A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Solid Tumor, Adult · Colorectal Cancer · NSCLC · Non Small Cell Lung Cancer · NSCLC, Recurrent · Non-Small Cell Squamous Lung Cancer · Pancreas Cancer · Pancreatic Neoplasm · Colorectal Adenocarcinoma · CRC · Colon Cancer · Rectal Cancer · Cancer · Ovarian Cancer · Ovarian Neoplasms · Mesothelioma · Mesothelioma, Malignant · Ovary Cancer · Lung Cancer · MESOM

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Banner Health, Gilbert, Arizona, United States
Contact: Study coordinator (Stephanie Kimmel) · Stephanie.Kimmel@bannerhealth.com
Contact: Principal Investigator (Matthew Ulrickson, MD)
UCSD Moores Cancer Center, La Jolla, California, United States
Contact: Study coordinator (Jona Plevin) · jplevin@health.ucsd.edu
Contact: Principal Investigator (Sandip Patel, MD)
UCLA Medical Center, Los Angeles, California, United States
Contact: Study coordinator (Nicole Williams) · NSowden@mednet.ucla.edu
Contact: Principal Investigator (J. Randolph Hecht, MD)
Stanford University, Stanford, California, United States
Contact: Study coordinator (Kayla McDaniel) · mcda59@stanford.edu
Contact: Principal Investigator (Oliver Dorigo, MD)
Mayo Clinic, Jacksonville, Florida, United States
Contact: Study coordinator (Rhoda Romain) · Romain.Rhoda@mayo.edu
Contact: Principal Investigator (Yanyan Lou, MD)
Moffitt Cancer Center, Tampa, Florida, United States
Contact: Study coordinator (Nathana Zelleke) · Nathana.Zelleke@moffitt.org
Contact: Principal Investigator (Monica Avila, MD)
Mayo Clinic Rochester, Rochester, Minnesota, United States
Contact: Study coordinator (Teri Heddlesten Rediske) · HeddlestenRediske.Teri@mayo.edu
Contact: Principal Investigator (Julian Molina, MD, PhD)
Washington University, St Louis, Missouri, United States
Contact: Study coordinator (Amberly Scott)
Study coordinator · amberly@wustl.edu
NYU Langone Medical Center, New York, New York, United States
Contact: Study coordinator (Salman Punekar, MD) · salman.punekar@nyulangone.org
Contact: Study coordinator (Peter Warren) · Peter.Warren@nyulangone.org
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Contact: Study coordinator (Dudbeth Brown) · Dudbeth.Brown@osumc.edu · 614-685-7034
Contact: Principal Investigator (Kai He, MD, PhD)
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Contact: Study coordinator (Vanderbilt-Ingram Cancer Center Clinical Trials Office (CTO) · CTIP@VUMC.ORG · 1-800-811-8480
Contact: Principal Investigator (Cathy Eng, M.D., FACP, FASCO)
Fred Hutchinson Cancer Center, Seattle, Washington, United States
Contact: Study coordinator (Shelby Colden)
Study coordinator · scolden2@fredhutch.org
Contact: Principal Investigator (David Zhen, MD)

Study leads

John Welch, MD, PhD
Study Director
A2 Biotherapeutics

View source on ClinicalTrials.gov Contact study team (email)